MedTrace Logo

Effects of Exenatide on Hypothalamic Obesity

NCT01061775 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-10-08

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index significantly from baseline.

Conditions

Interventions

DRUG

Exenatide

5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.

Sponsors & Collaborators

  • Amylin Pharmaceuticals, LLC.

    collaborator INDUSTRY

  • Children's Hospitals and Clinics of Minnesota

    lead OTHER

Principal Investigators

  • M. Jennifer Abuzzahab, MD · Children's Hospitals & Clinics of Minnesota

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-07-31
Completion
2019-03-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01061775 on ClinicalTrials.gov